“Ms. B” is another symptomatic volunteer who responded to an advertisement and enrolled in one of our trials. Three weeks later, we received a call from a colleague across town saying that Ms. B was already a subject in a trial at that site. This double enrollment was discovered when a pharmacy called the second site to verify a duplicate prescription for a controlled substance. Mr. A and Ms. B are two problematic volunteers whom we have identified in our own clinical trial program over the past year. We worry, however, that there may be similar subjects we are not aware of. In a fall 2009 article about the U.S. pharmaceutical industry moving clinical trials overseas, a Wyeth executive noted that “the trend toward placebo results and so-called failed trials is increasing in the United States. That means we are getting 'fake' patients, treatment-resistant patients, or patients who have been recycled from other studies” (5). Shiovitz et al. (6) recently described similar cases of “professional subjects” and were told anonymously by trial sponsors that duplicate subjects in some protocols have been as high as 5%.